Glucosamine (and chondroitin) show a short-term statistical effect on pain and function in knee osteoarthritis, but the clinical significance of that effect is small and uncertain. In the long term, only glucosamine sulphate has been shown to have a modest pain effect; its safety profile is favourable.
Glucosamine and chondroitin are popular supplements for people with joint complaints, particularly knee osteoarthritis. In the short term, studies show a statistically demonstrable reduction in pain and improvement in function when both agents are combined (1500 mg glucosamine and 1200 mg chondroitin per day). However, whether that effect is also genuinely noticeable to the patient is questionable. The effect size is small to moderate, and the clinical relevance remains unclear (PMID 22230308, 40647198, 29018060).
In the medium and long term, the picture is less positive. A meta-analysis of randomised trials (BJSM 2018, PMID 29018060) found that glucosamine and chondroitin had no clinically meaningful effect on pain or function. Only glucosamine sulphate showed a statistically significant reduction in pain compared with placebo after a minimum of 12 months, as shown by a large meta-analysis in JAMA (PMID 30575881). The uncertainty surrounding that effect is considerable, however, and the researchers emphasise that more research is needed.
There is also some evidence that long-term use of glucosamine sulphate and chondroitin sulphate can slow structural joint damage, measured as less joint space narrowing. Glucosamine sulphate performed better in this regard than chondroitin sulphate. Even so, the same caveats apply: the quality of evidence is limited, the uncertainty is great, and these results have not yet been translated into hard clinical endpoints such as fewer operations or better mobility (PMID 30575881).
On the safety side, there is good news: in most studies, glucosamine and chondroitin were well tolerated, with side effects comparable to placebo. No clinically relevant safety risks have been demonstrated at commonly used doses (PMID 40647198, 29018060).
In summary, the evidence for glucosamine in joint complaints is mixed. There is a statistical signal, but whether that makes daily supplementation worthwhile depends on the expectations of the user. People hoping for clear pain relief comparable to a medication will likely be disappointed. People who are satisfied with a modest and potentially structure-protecting effect, and who do not want to risk side effects, can choose to use it on the basis of the current evidence.
Five controlled claims, based on multiple meta-analyses and systematic reviews of RCTs (PMID 22230308, 40647198, 29018060, 30575881). The quality of evidence is predominantly moderate: studies are heterogeneous, effect sizes are small, and the clinical relevance of statistical effects has been repeatedly contested.